Industry News

Sernova Corp., a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today the appointment of Scott Langille as Chief Financial Officer. "Sernova is pleased to have attracted a senior executive with extensive experience in corporate and operational finance, in all facets of life sciences including brand and..."/>
Sernova Announces Appointment of New CFO
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal fourth quarter and fiscal year end 2016 financial results conference call on Thursday, October 13 at 1:15 PM PT/4: 15 PM ET. To listen to the conference call, please dial 731-1960 and use conference ID number: 91814044. An archived version of the presentation will be available for 90 days on..."/>
OncoSec to Host Fourth Quarter and Fiscal Year End Financial Results Conference Call on October 13, 2016
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it will hold its 2016 Annual Meeting of Shareholders on Monday, November 7, 2016 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of September 23, 2016 will be eligible to vote and are invited to attend."/>
Sinovac Schedules 2016 Annual Meeting of Shareholders
Agilent Technologies Inc. and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system. Agilent is the leading provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the entire..."/>
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics
UnitedHealth Group are establishing an innovative model for a collaborative approach to health care that will improve patient care for Californians. The 10- year strategic relationship will help transition California to a value-based health care system while leveraging the expertise of each organization to examine broader trends in care delivery. UC Health and UnitedHealth Group's Optum and UnitedHealthcare businesses will promote..."/>
University of California and UnitedHealth Group to Collaborate, Work Strategically to Improve Health Care
UnitedHealth Group, are taking immediate action to help people in Iowa who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate arrangements to ensure continuity of care and access to early prescription refills, as well as a free emotional-support line to help people in affected communities. *Help Finding a Network Care..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Iowa
UnitedHealth Group are establishing an innovative model for a collaborative approach to health care that will improve patient care for Californians. The 10- year strategic relationship will help transition California to a value-based health care system while leveraging the expertise of each organization to examine broader trends in care delivery. UC Health and UnitedHealth Group's Optum and UnitedHealthcare..."/>
University of California and UnitedHealth Group to Collaborate, Work Strategically to Improve Health Care
Verastem, Inc. and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non small cell lung and pancreatic cancers. The trial will run through the ECMC network at centres in Edinburgh-Dundee, Southampton, Glasgow, Leicester and Belfast."/>
Cancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs
SOFF: Solstad Offshore ASA's banks approve the Financing Plan
ANGLE plc. RESEARCH DEMONSTRATES POTENTIAL USE OF PARSORTIX IN ASSESSING CHEMOTHERAPY RESISTANCE. Fourth peer-reviewed publication- highlights key Parsortix advantages."/>
ANGLE PLC: Research Published in Clinical Chemistry
Bionor Pharma ASA."/>
Bionor Pharma - Preliminary result of the rights issue
Lupin Ltd., India's third largest drug maker, on Thursday said it has received approval to market generic version of Allergan Plc's Namenda extended release capsules in US market. Lupin got approval for 7 milligram, 14 mg, 21 mg and 28 mg capsules. Namenda generically called as memantine hydrochloride is used for treatment of moderate to severe dementia of the Alzheimer's type."/>
BRIEF: Lupin gets USFDA nod for generic dementia drug [Mint, New Delhi]
Apollo Hospitals Enterprise Ltd, India's largest healthcare provider, on Thursday said it has entered the medical rehabilitation services business in a joint venture with Italy-based KOS group. The equal joint venture, ApoKos, opened its first 64- bedded medical rehabilitation facility in Hyderabad, built at an estimated cost of Rs.20 crore, excluding land and building expenses. Apollo said the joint venture will be setting up similar medical..."/>
Apollo Hospitals, Italy-based KOS group to set up network of rehab facilities in India [Mint, New Delhi]
Agilent Technologies Inc. and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system. Agilent is the leading provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the..."/>
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics; Companies Collaborate in Their Aim to Accelerate Accurate Diagnosis
Amgen, one of the world's leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start, with the potential for another $600 million or more in the future. Arrowhead is based in Pasadena, California but most of its research-- including work on these two drugs-- is conducted in Madison, at 465 Science Drive, where the company has about 100 employees."/>
Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up to $673 million [The Wisconsin State Journal]
medical marijuana industry, an obvious question emerges: Where do doctors stand on pot? The medical establishment dismisses weed as scientifically untested, but some individual doctors are breaking ranks to back Amendment 2, the ballot question that will be decided Nov. 8.. The 20,000- member Florida Medical Association opposes Amendment 2."/>
Florida doctors have mixed opinions about medical marijuana [The Palm Beach Post, Fla.]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology698 Articles
Consumer Discretionary594 Articles
Financials457 Articles
Industrials387 Articles
Health Care384 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.